This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment
Cancer Cell International Open Access 30 July 2022
-
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Journal of Hematology & Oncology Open Access 09 October 2021
-
CAR-T-Zell-Therapie beim multiplen Myelom
Der Internist Open Access 03 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deaglio S, Mehta K, Malavasi F . Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1–12.
Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother 2009; 32: 737–743.
Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 3017–3025.
Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155: 925–937.
Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU . Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer 1995; 62: 337–344.
Bolognesi A, Polito L, Farini V, Bortolotti M, Tazzari PL, Ratta M et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents 2005; 19: 145–152.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.
Vooijs WC, Schuurman HJ, Bast EJ, de Gast GC . Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995; 85: 2282–2284.
Acknowledgements
We thank A Ihara (Fukuyama Central Hospital) and A Sakai (Hiroshima University) for providing invaluable comments and help.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mihara, K., Bhattacharyya, J., Kitanaka, A. et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 26, 365–367 (2012). https://doi.org/10.1038/leu.2011.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.205
This article is cited by
-
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment
Cancer Cell International (2022)
-
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Journal of Hematology & Oncology (2021)
-
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Bone Marrow Transplantation (2021)
-
CAR-T-Zell-Therapie beim multiplen Myelom
Der Internist (2021)
-
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
Journal of Hematology & Oncology (2017)